Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6111 USD | -1.42% | -6.13% | +79.63% |
May. 09 | Monopar Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 16 | Monopar Therapeutics Files Provisional Patent for New MNPR-101 Construct | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 173 | 70.09 | 40.42 | 30.62 | 5.058 | 10.67 | - | - |
Enterprise Value (EV) 1 | 173 | 70.09 | 40.42 | 30.62 | 5.058 | 10.67 | 10.67 | 10.67 |
P/E ratio | - | -10.6 x | -4.4 x | -2.86 x | -0.56 x | -1.67 x | -1.94 x | -2.22 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 10,421 | 11,452 | 12,591 | 12,920 | 14,866 | 17,455 | - | - |
Reference price 2 | 16.60 | 6.120 | 3.210 | 2.370 | 0.3402 | 0.6111 | 0.6111 | 0.6111 |
Announcement Date | 3/27/20 | 3/25/21 | 3/24/22 | 3/23/23 | 3/28/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - |
EBIT 1 | -4.324 | -6.509 | -9.127 | -10.54 | -8.831 | -6.69 | -9.369 | -9.865 |
Operating Margin | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -6.305 | -9.103 | -10.52 | -8.402 | -6.535 | -9.353 | -11.6 |
Net income 1 | - | -6.305 | -9.103 | -10.52 | -8.402 | -6.535 | -9.235 | -8.898 |
Net margin | - | - | - | - | - | - | - | - |
EPS 2 | - | -0.5800 | -0.7300 | -0.8300 | -0.6100 | -0.3650 | -0.3150 | -0.2750 |
Free Cash Flow | - | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 3/27/20 | 3/25/21 | 3/24/22 | 3/23/23 | 3/28/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -2.681 | -2.457 | -2.763 | -2.407 | -2.909 | -2.525 | -2.328 | -2.066 | -1.912 | -1.723 | -1.62 | -1.655 | -1.691 | - | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -15.53 | -2.457 | -2.763 | -2.4 | -2.896 | -2.435 | -2.2 | -1.954 | -1.814 | -1.641 | -1.588 | -1.63 | -1.676 | - | - |
Net income 1 | -15.53 | -2.457 | -2.763 | -2.4 | -2.896 | -2.435 | -2.2 | -1.954 | -1.814 | -1.641 | -1.588 | -1.63 | -1.676 | - | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.2100 | -0.1900 | -0.2200 | -0.1900 | -0.2300 | -0.1900 | -0.1600 | -0.1400 | -0.1200 | -0.1000 | -0.0900 | -0.0967 | -0.0933 | -0.0900 | -0.0900 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/24/22 | 5/12/22 | 8/11/22 | 11/10/22 | 3/23/23 | 5/11/23 | 8/10/23 | 11/9/23 | 3/28/24 | 5/9/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - | - |
Announcement Date | 3/27/20 | 3/25/21 | 3/24/22 | 3/23/23 | 3/28/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+79.63% | 10.67M | |
+44.48% | 55.07B | |
-0.86% | 41.79B | |
+43.51% | 40.22B | |
-7.59% | 28.17B | |
+12.30% | 26.28B | |
-21.83% | 18.93B | |
+7.15% | 13.03B | |
+29.40% | 12.26B | |
+25.15% | 12.21B |
- Stock Market
- Equities
- MNPR Stock
- Financials Monopar Therapeutics Inc.